Abstract
The authors report a new clinical manifestation of chronic myeloid leukemia. A 41-year-old man presented with significant visual loss, leading to a diagnosis of chronic myeloid leukemia. His white blood count exceeded that of any previously reported case of the disease with documented retinal findings (562,000/mm(3)), and clinical evaluation revealed the blockage of temporal retinal vessels by white blood cells. Hematologic findings resolved within 1 month of chemotherapy with dasatinib, and further treatment with intravitreal anti-VEGF agents resulted in the complete resolution of fundus findings. The authors propose that leukostasis retinopathy be recognized as a clinical manifestation of this life-threatening disease.
Copyright 2015, SLACK Incorporated.
MeSH terms
-
Adult
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Bevacizumab / therapeutic use
-
Dasatinib / therapeutic use
-
Fluorescein Angiography
-
Humans
-
Intravitreal Injections
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukocyte Count
-
Leukocytosis / diagnosis*
-
Leukocytosis / drug therapy
-
Leukostasis / diagnosis*
-
Leukostasis / drug therapy
-
Male
-
Polymerase Chain Reaction
-
Retinal Diseases / diagnosis*
-
Retinal Diseases / drug therapy
-
Tomography, Optical Coherence
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Visual Acuity
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
-
Dasatinib